154 related articles for article (PubMed ID: 15041382)
21. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
[TBL] [Abstract][Full Text] [Related]
22. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients.
Mandla R; Midtvedt K; Line PD; Hartmann A; Bergan S
Transpl Int; 2006 Jan; 19(1):44-53. PubMed ID: 16359376
[TBL] [Abstract][Full Text] [Related]
23. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics.
Kuriata-Kordek M; Boratynska M; Falkiewicz K; Porazko T; Urbaniak J; Wozniak M; Patrzalek D; Szyber P; Klinger M
Transplant Proc; 2003 Sep; 35(6):2369-71. PubMed ID: 14529944
[TBL] [Abstract][Full Text] [Related]
24. Alterations of cyclosporin A metabolism induced by mycophenolate mofetil.
Pape L; Froede K; Strehlau J; Ehrich JH; Offner G
Pediatr Transplant; 2003 Aug; 7(4):302-4. PubMed ID: 12890009
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).
Brunet M; Campistol JM; Millán O; Vidal E; Esforzado N; Rojo I; Jiménez O; Oppenheimer F; Corbella J; Martorell J
Int Immunopharmacol; 2003 Jul; 3(7):987-99. PubMed ID: 12810356
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.
Ghio L; Ferraresso M; Viganò SM; Ginevri F; Perfumo F; Gianoglio B; Murer L; Zacchello G; Dello Strologo L; Cardillo M; Tirelli S; Valente U; Edefonti A
Transplant Proc; 2005 Mar; 37(2):856-8. PubMed ID: 15848555
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of C2 monitoring in Korean renal transplantation.
Park JB; Han YS; Kim SJ; Choi GS; Kwon CH; Lee SK; Kim DJ; Joh JW
Transplant Proc; 2007 Dec; 39(10):3105-8. PubMed ID: 18089332
[TBL] [Abstract][Full Text] [Related]
28. The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.
Gustafsson F; Barth D; Delgado DH; Nsouli M; Sheedy J; Ross HJ
Eur J Clin Pharmacol; 2009 Jul; 65(7):659-65. PubMed ID: 19458944
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation.
Wacke R; Kundt G; Gock M; Klar E; Drewelow B; Schareck W
Transplant Proc; 2006 Apr; 38(3):751-2. PubMed ID: 16647462
[TBL] [Abstract][Full Text] [Related]
30. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients.
Falck P; Asberg A; Byberg KT; Bremer S; Bergan S; Reubsaet JL; Midtvedt K
Transplantation; 2008 Nov; 86(10):1379-83. PubMed ID: 19034006
[TBL] [Abstract][Full Text] [Related]
31. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
32. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
[TBL] [Abstract][Full Text] [Related]
33. Erythrocyte sodium lithium countertransport in renal transplant recipients with mycophenolate mofetil and low-dose cyclosporine.
Vareesangthip K; Hanlakorn P; Suwannaton L; Larpkitkachorn R; Chuawattana D; Pidetcha P; Ong-Aj-Yooth L
Transplant Proc; 2004 Dec; 36(10):3032-5. PubMed ID: 15686688
[TBL] [Abstract][Full Text] [Related]
34. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction.
Cantarovich M; Tzimas GN; Barkun J; Deschênes M; Alpert E; Tchervenkov J
Transplantation; 2003 Jul; 76(1):98-102. PubMed ID: 12865793
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporine levels at 2 hours after dose and body mass index in relation to graft function in renal transplant patients treated with azathioprine or mycophenolate mofetil.
Konstadinidou I; Giapraka N; Lionaki S; Kyriaki-Manolaraki D; Kostakis A; Stathakis CP; Boletis JN
Transplant Proc; 2004; 36(6):1753-6. PubMed ID: 15350469
[TBL] [Abstract][Full Text] [Related]
39. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
40. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
Balshaw R; Machnicki G; Carreño CA; Toselli L; Otero A; Keown PA
Transplant Proc; 2005 Mar; 37(2):871-4. PubMed ID: 15848560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
